|
Treatment compliance |
||
| n = 169 cycles |
||
| No. |
% |
|
|
|
||
| Delay 1st day |
||
| 1–8 days |
3 |
1.8 |
| 9–15 days |
3 |
1.8 |
| > 15 days |
1 |
0.6 |
| Delay 6th day |
||
| +1 |
11 |
6.5 |
| +2 |
8 |
4.7 |
| +3 |
5 |
3.0 |
| > +3 |
4 |
2.4 |
| n = 169 cycles |
||
| No. |
% |
|
|
|
||
| Dose reduction of all drugs |
||
| ≤ 25% |
18 |
10.6 |
| 26–50% |
5 |
3.0 |
| > 50% |
0 |
0 |
| Dose reduction of only A-T |
||
| ≤ 25% |
3 |
1.8 |
| 26–50% |
4 |
2.4 |
| > 50% |
0 |
0 |
| Dose reduction of only GEM |
||
| ≤ 25% |
2 |
1.2 |
| 26–50% |
7 |
4.1 |
| > 50% |
0 |
0 |
|
A, doxorubicin; T, paclitaxel; GEM, gemcitabine | ||
Passardi et al. BMC Cancer 2006 6:76 doi:10.1186/1471-2407-6-76 |
||